 |
|
|
Featured Antibody Family
Neuroscience
|
| |
New Ultra Sensitive BetaMark™
Beta Amyloid ELISA Assays
x-40 BetaMark ELISA
x-42 BetaMark ELISA
Covance’s two new BetaMark ELISA kits for beta amyloid x-40 and x-42, offer researchers ultra sensitive tools for investigating the diagnostic and therapeutic value of these two beta amyloid peptides. Alzheimer’s is a disease that presently affects over five million people, a number that is expected to quadruple over the next fifteen years. There is no known cure and diagnosis can only be confirmed post mortem. Cerebrovascular deposition of beta amyloid protein is a common pathologic event in Alzheimer’s disease and certain related neurodegenerative disorders, and there is compelling evidence that the c-terminal cleavage point of beta amyloid determines the aggregation potential of the peptide.
Covance offers a range of new discover tools in the field of Alzheimer’s/Parkinson’s and other Neurodenerative diseases. These include antibodies against the gamma secretase complex, synucleins, NMDA receptor, tau, phosphorylated tau’s and Amyloid beta. Covance’s Neuronal Class III β-Tubulin monoclonal TUJ1 and polyclonal antibodies and Tyrosine Hydroxylase are recognized as key standards for marking neuronal cells.
With the acquisition of Signet Laboratories in 2006, Covance added to this repertoire with the gold standard 4G8 and 6E10 amyloid beta and the 3F4 Prion antibodies (offered exclusively through Covance). We also offer subunit specific antibodies to the acetylcholine receptors and SNARE machinery.
More>> |
|
| |
|
|
| |
|
| New at
Antibody Products |
| July 28, 2008 - Covance Adds New Monoclonal Antibody to Cancer Research Portfolio |
|
--Vascular endothelial marker Endoglin (CD105) clone SN6h now available--
PRINCETON, NJ – July 28, 2008 – Covance Inc. (NYSE:CVD), a leading provider of drug development services, today announced the availability of Endoglin (CD105) clone SN6h, a new antibody utilized by anatomic pathologists and cancer researchers.
Endoglin (CD-105) is a component of the transforming growth factor (TGF)-beta receptor complex of human pre-B leukemic cells. Research has shown that endoglin is an optimal indicator of human endothelial cell proliferation and may also be i More>> |
|
|
|
|
| January 22, 2007 - Covance Becomes Exclusive Provider of Neuroscience Gold Standard Antibodies 6E10 and 4G8 for Alzheimer’s Disease, 3F4 for Prion Diseases |
|
--Covance now offers the industry’s most comprehensive list of neuroimmunology tools--
Princeton, NJ - January 22, 2007 - Covance (NYSE: CVD) today announced that it will now be the exclusive provider of neuroscience gold standard antibodies beta amyloid 6E10 and 4G8 for Alzheimer’s disease and 3F4 for prion disease research.
These antibodies head up the most comprehensive list of neuroimmunology tools available to the academic, biotech, and pharmaceutical industries. With the recent acquisition of Signet Laboratories, Covance has strengthened its position More>> |
|
|
| **Click here for more News & Events >> |
|
|
|
|
|
|
